VETOQUINOL (FR:VETO)
:VETO
Want to see FR:VETO full AI Analyst Report?
Top Page
VETOQUINOL
(VETO)
Select Model
Select Model
Rating:66Neutral
Price Target:
€80.00
▼(-5.21% Downside)
Action:Downgraded
Date:05/09/26
The score is primarily supported by strong financial quality (very low leverage and solid profitability), but is pulled down by weak technicals (price below key moving averages with negative MACD) and only moderate valuation support (reasonable P/E and modest dividend yield).
Positive Factors
Conservative balance sheet
Very low leverage and rising equity/assets materially reduce refinancing and solvency risk, giving the company durable financial flexibility. Over a 2–6 month horizon this supports capital allocation for R&D, manufacturing continuity and dividend policy without reliance on volatile funding markets.
Negative Factors
Weak revenue momentum
A downshift to slight revenue decline in 2025 signals weakened top-line momentum versus prior stability. If this trend persists it could constrain margin recovery and reinvestment capacity, making future growth dependent on product launches, pricing or market share gains rather than organic trend continuation.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and rising equity/assets materially reduce refinancing and solvency risk, giving the company durable financial flexibility. Over a 2–6 month horizon this supports capital allocation for R&D, manufacturing continuity and dividend policy without reliance on volatile funding markets.
Read all positive factors
VETOQUINOL (VETO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€851.48M
Dividend Yield1.06%
Average Volume (3M)5.40K
Price to Earnings (P/E)17.3
Beta (1Y)0.44
Revenue Growth-2.51%
EPS Growth-1.20%
CountryFR
Employees2,519
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.82
Shares Outstanding11,881,902
10 Day Avg. Volume4,099
30 Day Avg. Volume5,401
Financial Highlights & Ratios
PEG Ratio-21.56
Price to Book (P/B)1.68
Price to Sales (P/S)1.89
P/FCF Ratio19.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€110.00Price Target Upside30.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)5.26
Revenue Forecast (FY)€528.67M
VETOQUINOL Business Overview & Revenue Model
Company Description
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammatio...
How the Company Makes Money
Vetoquinol makes money primarily by selling animal health products (veterinary medicines and related health products) to customers in the veterinary and animal production value chain. Revenue is generated from (1) sales of proprietary (brand) prod...
VETOQUINOL Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 525.70M | 539.20M | 529.27M | 539.78M | 521.27M |
| Gross Profit | 160.36M | 387.45M | 291.38M | 172.37M | 167.37M |
| EBITDA | 348.90M | 114.08M | 112.33M | 103.46M | 116.86M |
| Net Income | 57.30M | 58.69M | 55.56M | 47.99M | 62.86M |
Balance Sheet | |||||
| Total Assets | 763.63M | 744.13M | 692.23M | 651.85M | 624.56M |
| Cash, Cash Equivalents and Short-Term Investments | 221.08M | 206.33M | 147.46M | 93.71M | 69.00M |
| Total Debt | 15.29M | 21.12M | 17.63M | 17.42M | 15.38M |
| Total Liabilities | 172.19M | 168.20M | 165.12M | 167.19M | 183.21M |
| Stockholders Equity | 591.37M | 575.84M | 527.01M | 484.57M | 441.26M |
Cash Flow | |||||
| Free Cash Flow | 51.35M | 68.15M | 70.38M | 39.90M | 56.76M |
| Operating Cash Flow | 72.08M | 85.83M | 89.39M | 62.39M | 89.17M |
| Investing Cash Flow | -20.56M | -15.65M | -18.88M | -21.52M | -33.45M |
| Financing Cash Flow | -25.08M | -16.03M | -15.50M | -16.06M | -120.31M |
VETOQUINOL Technical Analysis
Negative
84.40
Price Trends
77.81
Negative
81.59
Negative
78.59
Negative
Market Momentum
-2.19
Positive
38.26
Neutral
21.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VETO, the sentiment is Negative. The current price of 84.4 is above the 20-day moving average (MA) of 75.92, above the 50-day MA of 77.81, and above the 200-day MA of 78.59, indicating a bearish trend. The MACD of -2.19 indicates Positive momentum. The RSI at 38.26 is Neutral, neither overbought nor oversold. The STOCH value of 21.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:VETO.
VETOQUINOL Peers Comparison
UnderperformOutperform
Sector (55)
FR:VETO
VETOQUINOL
72.00
-2.01
-2.72%
FR:VIRP
Virbac SA
360.00
49.40
15.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.